Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Anthem Biosciences IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2006 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 2512.03 Cr
Profile
Price Range 540  to  570 per share
Profile
Min Investment ₹570
Profile
Lot Size 1
Profile
Face Value ₹2
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

We are an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing. We are one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing, according to the F&S Report. As a one-stop service provider, we serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. We are one of the youngest Indian CRDMO companies and the fastest Indian CRDMO to achieve a milestone of ?10,000 million of revenue within 14 years of operations, reaching this milestone in Fiscal 2021, according to the F&S Report. We also recorded the highest revenue growth in Fiscal 2023 to Fiscal 2024 as compared to our peers in India and globally, according to the F&S Report. Read More

Basic Info

Face Value 2 per share

Price 540  to  570 per share

P/E (x) 70.4

Sales( Cr.) 1845

PAT( Cr.) 451

EPS 8.1

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Ajay Bhardwaj Ganesh Sambasivam K Ravindra Chandrappa Ishaan Bhardwaj

Pre Issue Share Holding 76.87%

Post Issue Share Holding 74.69%

Listing Details:

Listing Price: 723.1

Listing Gain: 21.17%

Current Price: 760

Gain On Issue: 760 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Jul 14, 2025
Closing Date Jul 16, 2025
Allotment Jul 17, 2025
Refund Jul 18, 2025
Delivery of Shares Jul 18, 2025
Listing Date Jul 21, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 26 14,820
Retail (Max) 13 338 192,660
S-HNI (Min) 14 364 207,480
S-HNI (Max) 67 1742 992,940
B-HNI (Min) 68 1768 1,007,760

Objective of the Issue

Issue

Category Nos Bid Bid (x)
QIB 12543518 2291095976 182.7x
NII 9407639 398469578 42.4x
Retail 21951158 123847828 5.6x
EMP 168367 1110746 6.6x
Total 44070682 2814524128 63.9x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Anthem Biosciences Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 82 129 248 308 356 633 1103 1231 1057 1419 1845
Other Income 1 2 3 5 7 21 37 49 85 64 86
Total Income 83 130 251 313 363 653 1140 1280 1142 1483 1930
Total Expenditure 58 94 178 215 248 451 696 664 634 914 1174
Operating Profit 25 36 73 98 115 203 445 616 508 569 757
Interest 3 4 6 5 5 20 17 12 9 10 11
Depreciation 5 8 10 21 22 62 62 58 64 82 89
Exceptional Income / Expenses 0 0 0 -0 0 0 0 0 62 0 0
Profit Before Tax 17 25 58 73 88 121 366 546 497 477 657
Provision for Tax -0 8 19 23 22 28 94 141 112 110 206
Profit After Tax 17 16 39 50 66 93 271 406 385 367 451
Adjustments 0 -0 -0 -0 0 0 0 0 0 0 0
Profit After Adjustments 17 16 39 50 66 93 271 406 385 367 451
Adjusted Earnings Per Share 0.3 0.3 0.7 0.9 1.2 1.7 4.9 7.1 6.8 6.6 8.1

Anthem Biosciences Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 38 64 102 151 223 422 701 1355 1741 1925 2410
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 19 45 51 83 156 95 20 6 96 112 47
Other Non-Current Liabilities 1 3 6 3 5 11 14 16 -11 -18 7
Total Current Liabilities 43 69 76 119 126 247 356 349 279 459 485
Total Liabilities 102 181 235 355 510 776 1091 1726 2105 2477 2949
Fixed Assets 37 87 91 86 258 306 361 329 449 483 705
Other Non-Current Assets 21 15 37 90 57 67 43 181 217 393 348
Total Current Assets 43 79 107 179 194 403 687 1216 1438 1602 1896
Total Assets 102 181 235 355 510 776 1091 1726 2105 2477 2949

Anthem Biosciences Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 14 22 41 349 343 184
Cash Flow from Operating Activities 0 0 0 0 0 166 278 333 306 140 418
Cash Flow from Investing Activities 0 0 0 0 0 -109 -196 -205 -376 -221 -152
Cash Flow from Financing Activities 0 0 0 0 0 -48 -63 181 64 -77 -134
Net Cash Inflow / Outflow 0 0 0 0 0 9 18 308 -6 -158 133
Closing Cash & Cash Equivalent 0 0 0 0 0 22 41 349 343 184 317

Anthem Biosciences Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.34 0.3 0.71 0.91 1.21 1.7 4.92 7.11 6.75 6.57 8.07
CEPS(Rs) 0.44 0.44 0.9 1.3 1.61 2.83 6.05 8.12 7.87 8.03 9.67
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0.77 1.08 1.79 2.68 4.06 7.75 12.72 23.75 30.51 34.43 42.49
Core EBITDA Margin(%) 29.46 26.78 28.32 30.37 30.4 28.75 36.96 46.06 40.01 35.59 36.38
EBIT Margin(%) 24.29 22.26 25.51 25.25 26.29 22.3 34.67 45.35 47.88 34.31 36.18
Pre Tax Margin(%) 20.07 19.21 23.28 23.62 24.76 19.07 33.14 44.36 47.05 33.63 35.61
PAT Margin (%) 20.19 12.73 15.72 16.27 18.56 14.65 24.59 32.94 36.44 25.88 24.46
Cash Profit Margin (%) 26.13 18.61 19.82 22.92 24.61 24.38 30.25 37.63 42.47 31.64 29.31
ROA(%) 16.35 11.66 18.74 16.98 15.28 14.42 29.07 28.79 20.11 16.04 16.64
ROE(%) 44.14 34.19 49.99 41.23 36.02 28.84 48.3 39.44 24.89 20.04 20.99
ROCE(%) 25.6 26.7 39.87 34.59 27.35 28.38 55.36 50.94 31.08 24.21 28.55
Receivable days 43.64 56.96 64.47 83.42 80.79 51.59 59.51 86.09 103.65 98.3 93.09
Inventory Days 68.34 66 50.36 49.58 53.59 52.86 26.55 13.83 32.4 43.81 54.59
Payable days 174.58 161.93 85.46 69.81 79.59 66.55 54.41 63.27 73.58 52.56 51.72
PER(x) 0 0 0 0 0 0 0 0 0 0 0
Price/Book(x) 0 0 0 0 0 0 0 0 0 0 0
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.56 0.66 0.36 0.42 0.53 0.23 0.06 -0.25 -0.1 0.11 -0.05
EV/Core EBITDA(x) 1.86 2.32 1.21 1.31 1.65 0.71 0.15 -0.49 -0.2 0.28 -0.13
Net Sales Growth(%) 0 57.01 92.77 24.27 15.49 77.75 74.36 11.6 -14.16 34.29 29.96
EBIT Growth(%) 0 44.17 119.61 23 20.26 50.78 171.1 45.96 -9.37 -3.76 37.05
PAT Growth(%) 0 -0.82 136.8 28.57 31.79 40.29 192.65 49.48 -5.02 -4.64 22.86
EPS Growth(%) 0 -11.3 134.96 28.83 32.08 40.92 189.04 44.52 -5.03 -2.69 22.85
Debt/Equity(x) 1.07 1.16 0.76 0.79 0.85 0.38 0.14 0.03 0.07 0.12 0.05
Current Ratio(x) 1 1.14 1.41 1.51 1.54 1.63 1.93 3.48 5.16 3.49 3.91
Quick Ratio(x) 0.64 0.69 0.92 1.12 1.08 1.12 1.83 3.32 4.69 3.03 3.21
Interest Cover(x) 5.76 7.3 11.47 15.53 17.24 6.91 22.55 45.81 58.01 50.43 63.4
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 30% 14% 24% 37%
Operating Profit CAGR 33% 7% 30% 41%
PAT CAGR 23% 4% 37% 39%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 21% 22% 31% 35%
ROCE Average 29% 28% 38% 34%

Company Contact Information

Anthem Biosciences Ltd.

Divya Prasad

91 080 6672 4000

investors.abl@anthembio.com

No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area Phase I, Bommasandra

IPO Lead Manager(s)

Anthem Biosciences Ltd.

JM Financial Ltd.

Citigroup Global Markets India Pvt Ltd.

JP Morgan India Pvt Ltd

Nomura Financial Advisory & Securities (India) Pvt Ltd.

Registrar Info

Anthem Biosciences Ltd.

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District, Nanakramguda Hyderabad – 500032 Tel. No. 040 67161500 Fax. No. 040 23001153 E-mail: einward.ris@karvy.com Website: www.karvy.com Toll Free No. of exclusive Call Centre:1-800-345001

040 - 67162222/18003094001

einward.ris@kfintech.com

https://www.kfintech.com

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!